pharmaceutical investing Novartis Advanced Accelerator Applications Receives FDA Approval for Lutathera
pharmaceutical investing Novartis completes tender offer for Advanced Accelerator Applications S.A. and commencement of subsequent offering period
Advanced Accelerator Applications Announces Pricing of $150 Million Public Offering of American Depositary Shares
ITEL signs agreement with Advanced Accelerator Applications to commercialize F-18 radiopharmaceuticals in Southern Italy
Quebec Innovative Materials:Advancing Canadian and American Natural Hydrogen for the Next Energy Cycle